Doxazosin-to-terazosin switch for benign prostatic hyperplasia.
作者信息
Jansen D J, Resch N D, Hoffman R M
出版信息
Am J Health Syst Pharm. 1999 Jul 1;56(13):1351. doi: 10.1093/ajhp/56.13.1351a.
PMID:10683137
Abstract
摘要
相似文献
1
Doxazosin-to-terazosin switch for benign prostatic hyperplasia.
Am J Health Syst Pharm. 1999 Jul 1;56(13):1351. doi: 10.1093/ajhp/56.13.1351a.
2
Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia.坦索罗辛、多沙唑嗪和特拉唑嗪治疗良性前列腺增生的成本效益
J Manag Care Pharm. 2004 Sep-Oct;10(5):412-22. doi: 10.18553/jmcp.2004.10.5.412.
3
Terazosin, doxazosin, and prazosin: current clinical experience.特拉唑嗪、多沙唑嗪和哌唑嗪：当前临床经验
Urology. 2001 Dec;58(6 Suppl 1):49-54. doi: 10.1016/s0090-4295(01)01302-4.
4
Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders.特拉唑嗪和多沙唑嗪治疗良性前列腺增生：无反应者交叉随机研究结果
Urol Int. 2004;73(2):125-9. doi: 10.1159/000079692.
5
The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years.80岁以上男性使用α受体阻滞剂治疗良性前列腺增生症
Br J Urol. 1997 Dec;80(6):875-9. doi: 10.1046/j.1464-410x.1997.00471.x.
6
7
Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.多沙唑嗪和特拉唑嗪通过诱导细胞凋亡抑制前列腺生长：临床意义。
J Urol. 2003 Apr;169(4):1520-5. doi: 10.1097/01.ju.0000033280.29453.72.
8
[Alpha blockers in the treatment of benign hyperplasia of the prostate].
Rev Clin Esp. 1997 May;197(5):358-62.
9
Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (Part One).多沙唑嗪——一种用于良性前列腺增生长期治疗的α1受体阻断剂（第一部分）
Int Urol Nephrol. 1995;27(3):311-8. doi: 10.1007/BF02564768.
10
[Prostatic adenoma: new drugs, new surgical techniques].
Med Monatsschr Pharm. 1992 Dec;15(12):362-4.
Zotero 插件